{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:42:45Z","timestamp":1787161365782,"version":"build-2736575974"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013017","name":"Vanderbilt University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH073676"],"award-info":[{"award-number":["R01MH073676"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH122545"],"award-info":[{"award-number":["R01MH122545"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bbr.2021.113201","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T12:17:52Z","timestamp":1614341872000},"page":"113201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["Targeting muscarinic receptors to treat schizophrenia"],"prefix":"10.1016","volume":"405","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5225-354X","authenticated-orcid":false,"given":"Daniel J.","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-873X","authenticated-orcid":false,"given":"Zoey K.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Jeffrey","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20133","key":"10.1016\/j.bbr.2021.113201_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cjust the facts\u201d 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.bbr.2021.113201_bib0010","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.bbr.2021.113201_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF03402101","article-title":"Schizophrenia: neural mechanisms for novel therapies","volume":"9","author":"Sawa","year":"2003","journal-title":"Mol. Med."},{"issue":"8","key":"10.1016\/j.bbr.2021.113201_bib0020","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2021.113201_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S0033291717001775","article-title":"The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum","volume":"48","author":"Guloksuz","year":"2018","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2014the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2021.113201_bib0035","first-page":"1","article-title":"Schizophrenia-an overview","author":"McCutcheon","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bbr.2021.113201_bib0040","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J."},{"issue":"4","key":"10.1016\/j.bbr.2021.113201_bib0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbr.2021.113201_bib0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pnpbp.2017.11.004","article-title":"Side effect burden of antipsychotic drugs in real life\u2014impact of gender and polypharmacy","volume":"82","author":"Iversen","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3\u20134","key":"10.1016\/j.bbr.2021.113201_bib0060","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00213-003-1505-z","article-title":"Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol","volume":"169","author":"Purdon","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.bbr.2021.113201_bib0065","first-page":"117","article-title":"Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics","volume":"9","author":"Lally","year":"2016","journal-title":"Pers. Med."},{"key":"10.1016\/j.bbr.2021.113201_bib0070","series-title":"Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014","year":"2014"},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0075","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","article-title":"Treatment of the neuroleptic-nonresponsive schizophrenic patient","volume":"18","author":"Meltzer","year":"1992","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.bbr.2021.113201_bib0080","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/0006-3223(93)90043-D","article-title":"Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine","volume":"34","author":"Hagger","year":"1993","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2014a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0090","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bbr.2021.113201_bib0095","first-page":"261","article-title":"Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4","volume":"7","author":"Seeman","year":"1992","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0893-133X(98)00048-7","article-title":"Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells","volume":"20","author":"Olianas","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0110","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0922-4106(94)90047-7","article-title":"Clozapine is a potent and selective muscarinic M4 receptor agonist","volume":"269","author":"Zorn","year":"1994","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-2999(91)90096-9","article-title":"Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells","volume":"192","author":"Bolden","year":"1991","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.bbr.2021.113201_bib0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","article-title":"The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine","volume":"177","author":"Weiner","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.bjp.0701357","article-title":"Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor","volume":"122","author":"Olianas","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1124\/dmd.112.050484","article-title":"Characterization of human cytochrome P450s involved in the bioactivation of clozapine","volume":"41","author":"Dragovic","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"23","key":"10.1016\/j.bbr.2021.113201_bib0135","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","article-title":"N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity","volume":"100","author":"Sur","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bbr.2021.113201_bib0140","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1177\/0269881117731278","article-title":"Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats","volume":"31","author":"Miyauchi","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.bbr.2021.113201_bib0145","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1124\/jpet.116.235788","article-title":"Positive allosteric modulation of the muscarinic M1 receptor improves efficacy of antipsychotics in mouse glutamatergic deficit models of behavior","volume":"359","author":"Choy","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.bbr.2021.113201_bib0150","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.npp.1300768","article-title":"N-Desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors","volume":"30","author":"Li","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2021.113201_bib0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.psychres.2017.10.010","article-title":"Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients","volume":"258","author":"Molins","year":"2017","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.bbr.2021.113201_bib0160","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.2015.14050673","article-title":"Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine","volume":"172","author":"Rajji","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2021.113201_bib0165","unstructured":"Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics. https:\/\/ClinicalTrials.gov\/show\/NCT00628420."},{"key":"10.1016\/j.bbr.2021.113201_bib0170","series-title":"Acadia Pharmaceuticals","year":"2008"},{"key":"10.1016\/j.bbr.2021.113201_bib0175","unstructured":"A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia. https:\/\/ClinicalTrials.gov\/show\/NCT04136873."},{"issue":"7","key":"10.1016\/j.bbr.2021.113201_bib0180","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.npp.1301279","article-title":"Evaluation of N-desmethylclozapine as a potential antipsychotic\u2014preclinical studies","volume":"32","author":"Natesan","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.bbr.2021.113201_bib0185","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","article-title":"Clozapine. A novel antipsychotic agent","volume":"324","author":"Baldessarini","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbr.2021.113201_bib0190","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2018.11.030","article-title":"An investigation into the relationship between clozapine treatment and cognitive performance in patients with treatment resistant schizophrenia","volume":"206","author":"McArdle","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2021.113201_bib0195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-3-642-25758-2_10","article-title":"Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications","volume":"213","author":"Coyle","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.bbr.2021.113201_bib0205","doi-asserted-by":"crossref","first-page":"e1147","DOI":"10.1038\/tp.2017.124","article-title":"Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis","volume":"7","author":"Egerton","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/npp.2011.199","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia","volume":"37","author":"Jones","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0215","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neuron.2017.03.016","article-title":"Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders","volume":"94","author":"Foster","year":"2017","journal-title":"Neuron"},{"issue":"22","key":"10.1016\/j.bbr.2021.113201_bib0220","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1001\/jama.1982.03320470029019","article-title":"Transdermal scopolamine psychosis","volume":"247","author":"Osterholm","year":"1982","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0920-9964(91)90006-D","article-title":"Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms","volume":"4","author":"Tandon","year":"1991","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.bbr.2021.113201_bib0230","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1046\/j.1460-9568.2003.02588.x","article-title":"Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity","volume":"17","author":"Bymaster","year":"2003","journal-title":"Eur. J. Neurosci."},{"issue":"4","key":"10.1016\/j.bbr.2021.113201_bib0235","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"issue":"Suppl 4","key":"10.1016\/j.bbr.2021.113201_bib0240","first-page":"S16","article-title":"The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease","volume":"11","author":"Bodick","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"8","key":"10.1016\/j.bbr.2021.113201_bib0245","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.bbr.2021.113201_bib0250","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska","year":"2003","journal-title":"World J. Urol."},{"issue":"6","key":"10.1016\/j.bbr.2021.113201_bib0255","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113201_bib0260","series-title":"Karuna Therapeutics","year":"2019"},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0265","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3565(25)38667-2","article-title":"Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors","volume":"269","author":"Shannon","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bbr.2021.113201_bib0270","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.0.CO;2-K","article-title":"Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer\u2019s disease","volume":"40","author":"Bymaster","year":"1997","journal-title":"Drug Dev. Res."},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0275","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/acschemneuro.8b00625","article-title":"Striatal, hippocampal, and cortical networks are differentially responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline","volume":"10","author":"Thorn","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.bbr.2021.113201_bib0280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2008.12.044","article-title":"Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists","volume":"605","author":"Heinrich","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.bbr.2021.113201_bib0285","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","article-title":"Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice","volume":"603","author":"Woolley","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.bbr.2021.113201_bib0290","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1021\/cn500128b","article-title":"Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents","volume":"5","author":"Bubser","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"31","key":"10.1016\/j.bbr.2021.113201_bib0295","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1073\/pnas.0800567105","article-title":"Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia","volume":"105","author":"Chan","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bbr.2021.113201_bib0300","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","article-title":"Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release","volume":"91","author":"Foster","year":"2016","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.bbr.2021.113201_bib0305","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/npp.2009.194","article-title":"Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties","volume":"35","author":"Leach","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.bbr.2021.113201_bib0310","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1476-5381.2010.01184.x","article-title":"Impact of species variability and\u2019 probe-dependence\u2019 on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor","volume":"162","author":"Suratman","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113201_bib0315","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2011.08.066","article-title":"Dopamine release in the basal ganglia","volume":"198","author":"Rice","year":"2011","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0320","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0306-4522(94)90017-5","article-title":"Localization of muscarinic m3 receptor protein and M3 receptor binding in rat brain","volume":"63","author":"Levey","year":"1994","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.bbr.2021.113201_bib0325","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<357::AID-SYN9>3.0.CO;2-B","article-title":"Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons","volume":"27","author":"Ince","year":"1997","journal-title":"Synapse"},{"issue":"8","key":"10.1016\/j.bbr.2021.113201_bib0330","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1523\/JNEUROSCI.16-08-02592.1996","article-title":"Muscarinic (m2\/m4) receptors reduce N- and P-type Ca2+ currents in rat neostriatal cholinergic interneurons through a fast, membrane-delimited, G-protein pathway","volume":"16","author":"Yan","year":"1996","journal-title":"J. Neurosci."},{"issue":"18","key":"10.1016\/j.bbr.2021.113201_bib0335","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1073\/pnas.87.18.7050","article-title":"Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia","volume":"87","author":"Weiner","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.bbr.2021.113201_bib0340","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1523\/JNEUROSCI.4896-13.2014","article-title":"M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor\u2019s location","volume":"34","author":"Foster","year":"2014","journal-title":"J. Neurosci."},{"issue":"26","key":"10.1016\/j.bbr.2021.113201_bib0345","doi-asserted-by":"crossref","first-page":"8124","DOI":"10.1073\/pnas.1508846112","article-title":"Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens","volume":"112","author":"Shin","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"46","key":"10.1016\/j.bbr.2021.113201_bib0350","doi-asserted-by":"crossref","first-page":"11166","DOI":"10.1523\/JNEUROSCI.0596-17.2017","article-title":"Distinctive modulation of dopamine release in the nucleus accumbens shell mediated by dopamine and acetylcholine receptors","volume":"37","author":"Shin","year":"2017","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.bbr.2021.113201_bib0355","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1523\/JNEUROSCI.5620-09.2010","article-title":"Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum","volume":"30","author":"Threlfell","year":"2010","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.bbr.2021.113201_bib0360","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1021\/cn500003z","article-title":"M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses","volume":"5","author":"Pancani","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"6","key":"10.1016\/j.bbr.2021.113201_bib0365","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1523\/JNEUROSCI.3843-09.2010","article-title":"A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors","volume":"30","author":"Jeon","year":"2010","journal-title":"J. Neurosci."},{"issue":"16","key":"10.1016\/j.bbr.2021.113201_bib0370","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1523\/JNEUROSCI.0370-11.2011","article-title":"Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1\/M4 preferring muscarinic receptor agonist xanomeline","volume":"31","author":"Dencker","year":"2011","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.bbr.2021.113201_bib0375","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/hipo.22732","article-title":"Effects of M1 and M4 activation on excitatory synaptic transmission in CA1","volume":"27","author":"Thorn","year":"2017","journal-title":"Hippocampus"},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0380","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nchembio.2007.55","article-title":"An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission","volume":"4","author":"Shirey","year":"2008","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0385","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/acschemneuro.8b00496","article-title":"In vivo modulation of hippocampal excitability by M4 muscarinic acetylcholine receptor activator: implications for treatment of Alzheimer\u2019s disease and schizophrenic patients","volume":"10","author":"Popiolek","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"7","key":"10.1016\/j.bbr.2021.113201_bib0390","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/npp.2014.2","article-title":"Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100","volume":"39","author":"Byun","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2021.113201_bib0395","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuropharm.2017.07.013","article-title":"Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154","volume":"128","author":"Gould","year":"2018","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2021.113201_bib0400","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1021\/acs.jmedchem.9b01406","article-title":"Discovery of [(11)C]MK-6884: a positron emission tomography (PET) imaging agent for the study of M4 muscarinic receptor positive allosteric modulators (PAMs) in neurodegenerative diseases","volume":"63","author":"Tong","year":"2020","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bbr.2021.113201_bib0405","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1021\/acschemneuro.5b00123","article-title":"Role for the M1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice","volume":"6","author":"Gould","year":"2015","journal-title":"ACS Chem. Neurosci."},{"issue":"37","key":"10.1016\/j.bbr.2021.113201_bib0410","doi-asserted-by":"crossref","first-page":"15950","DOI":"10.1073\/pnas.0900903106","article-title":"Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation","volume":"106","author":"Ma","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bbr.2021.113201_bib0415","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/s41386-018-0033-9","article-title":"M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition","volume":"43","author":"Moran","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.bbr.2021.113201_bib0420","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1021\/acschemneuro.8b00131","article-title":"A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity","volume":"9","author":"Rook","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.bbr.2021.113201_bib0425","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41386-018-0168-8","article-title":"TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects","volume":"44","author":"Sako","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0430","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00213-019-05354-5","article-title":"Rescuing the attentional performance of rats with cholinergic losses by the M1 positive allosteric modulator TAK-071","volume":"237","author":"Kucinski","year":"2020","journal-title":"Psychopharmacology (Berl.)"},{"issue":"4","key":"10.1016\/j.bbr.2021.113201_bib0435","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neuron.2020.02.030","article-title":"Muscarinic M1 receptors modulate working memory performance and activity via KCNQ potassium channels in the primate prefrontal cortex","volume":"106","author":"Galvin","year":"2020","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0440","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.115.226712","article-title":"The M1 muscarinic positive allosteric modulator PQCA improves performance on translatable tests of memory and attention in Rhesus monkeys","volume":"355","author":"Lange","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bbr.2021.113201_bib0445","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/npp.2015.189","article-title":"Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model","volume":"41","author":"Ghoshal","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"45","key":"10.1016\/j.bbr.2021.113201_bib0450","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","article-title":"A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning","volume":"29","author":"Shirey","year":"2009","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.bbr.2021.113201_bib0455","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1152\/jn.00686.2010","article-title":"M1 and M4 receptors modulate hippocampal pyramidal neurons","volume":"105","author":"Dasari","year":"2011","journal-title":"J. Neurophysiol."},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0460","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cercor\/bhv227","article-title":"Activation of muscarinic M1 acetylcholine receptors induces long-term potentiation in the hippocampus","volume":"26","author":"Dennis","year":"2016","journal-title":"Cereb. Cortex"},{"issue":"43","key":"10.1016\/j.bbr.2021.113201_bib0465","doi-asserted-by":"crossref","first-page":"9252","DOI":"10.1523\/JNEUROSCI.1160-18.2018","article-title":"Convergent metabotropic signaling pathways inhibit SK channels to promote synaptic plasticity in the Hippocampus","volume":"38","author":"Tigaret","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2021.113201_bib0470","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fncel.2015.00457","article-title":"Endocannabinoids mediate muscarinic acetylcholine receptor-dependent long-term depression in the adult medial prefrontal cortex","volume":"9","author":"Martin","year":"2015","journal-title":"Front. Cell. Neurosci."},{"issue":"610","key":"10.1016\/j.bbr.2021.113201_bib0475","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aax2057","article-title":"Biased M1 receptor-positive allosteric modulators reveal role of phospholipase D in M1-dependent rodent cortical plasticity","volume":"12","author":"Moran","year":"2019","journal-title":"Sci. Signal."},{"issue":"12","key":"10.1016\/j.bbr.2021.113201_bib0480","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.biopsych.2019.02.020","article-title":"M1 muscarinic receptors modulate fear-related inputs to the prefrontal cortex: implications for novel treatments of posttraumatic stress disorder","volume":"85","author":"Maksymetz","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbr.2021.113201_bib0485","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1021\/acschemneuro.6b00230","article-title":"Prefrontal cortex-mediated impairments in a genetic model of NMDA receptor hypofunction are reversed by the novel M1 PAM VU6004256","volume":"7","author":"Grannan","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"10","key":"10.1016\/j.bbr.2021.113201_bib0490","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","article-title":"Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia","volume":"7","author":"Dean","year":"2002","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.bbr.2021.113201_bib0495","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.lfs.2005.06.038","article-title":"No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia","volume":"78","author":"Scarr","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.bbr.2021.113201_bib0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112989","article-title":"Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia","volume":"288","author":"Dean","year":"2020","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.bbr.2021.113201_bib0505","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1503\/jpn.170202","article-title":"Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia","volume":"43","author":"Scarr","year":"2018","journal-title":"J. Psychiatry Neurosci."},{"issue":"8","key":"10.1016\/j.bbr.2021.113201_bib0510","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2967\/jnumed.118.222034","article-title":"Evaluation of (11)C-LSN3172176 as a novel PET tracer for imaging M1 muscarinic acetylcholine receptors in nonhuman primates","volume":"60","author":"Nabulsi","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.bbr.2021.113201_bib0515","doi-asserted-by":"crossref","first-page":"E1089","DOI":"10.1073\/pnas.1516134113","article-title":"Cortical cholinergic signaling controls the detection of cues","volume":"113","author":"Gritton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0520","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuron.2007.08.025","article-title":"Prefrontal acetylcholine release controls cue detection on multiple timescales","volume":"56","author":"Parikh","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2021.113201_bib0525","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","article-title":"Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer\u2019s disease","volume":"4","author":"Voss","year":"2018","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"10.1016\/j.bbr.2021.113201_bib0530","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuroscience.2019.07.003","article-title":"In vivo pharmacological comparison of TAK-071, a positive allosteric modulator of muscarinic M1 receptor, and xanomeline, an agonist of muscarinic M1\/M4 receptor, in rodents","volume":"414","author":"Mandai","year":"2019","journal-title":"Neuroscience"},{"issue":"13","key":"10.1016\/j.bbr.2021.113201_bib0535","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1021\/acs.jmedchem.6b00544","article-title":"Discovery of the potent and selective M1 PAM-agonist N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)ben zyl]pyridine-2-carboxamide (PF-06767832): evaluation of efficacy and cholinergic side effects","volume":"59","author":"Davoren","year":"2016","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bbr.2021.113201_bib0540","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0026-895X(25)13594-3","article-title":"Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain","volume":"43","author":"Yasuda","year":"1993","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.bbr.2021.113201_bib0545","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1021\/acschemneuro.9b00274","article-title":"Acute negative allosteric modulation of M5 muscarinic acetylcholine receptors inhibits oxycodone self-administration and cue-induced reactivity with no effect on antinociception","volume":"10","author":"Gould","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"7","key":"10.1016\/j.bbr.2021.113201_bib0550","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/s41386-017-0007-3","article-title":"Muscarinic M5 receptors modulate ethanol seeking in rats","volume":"43","author":"Berizzi","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.bbr.2021.113201_bib0555","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1152\/jn.01120.2011","article-title":"Knockouts reveal overlapping functions of M(2) and M(4) muscarinic receptors and evidence for a local glutamatergic circuit within the laterodorsal tegmental nucleus","volume":"108","author":"Kohlmeier","year":"2012","journal-title":"J. Neurophysiol."},{"issue":"6","key":"10.1016\/j.bbr.2021.113201_bib0560","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.neuron.2017.12.008","article-title":"Cholinergic projections to the substantia nigra pars reticulata inhibit dopamine modulation of basal ganglia through the M4 muscarinic receptor","volume":"96","author":"Moehle","year":"2017","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0565","first-page":"297","article-title":"Effect of anticholinergics on positive and negative symptoms in schizophrenia","volume":"28","author":"Tandon","year":"1992","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.bbr.2021.113201_bib0570","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0166-4328(90)90024-9","article-title":"Differential effects of atropine, procaine and dopamine in the rat ventral tegmentum on lateral hypothalamic rewarding brain stimulation","volume":"38","author":"Kofman","year":"1990","journal-title":"Behav. Brain Res."},{"issue":"1\u20132","key":"10.1016\/j.bbr.2021.113201_bib0575","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(97)00928-1","article-title":"Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus","volume":"775","author":"Mathur","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.bbr.2021.113201_bib0580","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2015.04.002","article-title":"Ventral tegmental area cholinergic mechanisms mediate behavioral responses in the forced swim test","volume":"288","author":"Addy","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2021.113201_bib0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108089","article-title":"Examining the role of muscarinic M5 receptors in VTA cholinergic modulation of depressive-like and anxiety-related behaviors in rats","volume":"171","author":"Nunes","year":"2020","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2021.113201_bib0590","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/adb.12567","article-title":"Selective inhibition of M5 muscarinic acetylcholine receptors attenuates cocaine self-administration in rats","volume":"23","author":"Gunter","year":"2018","journal-title":"Addict. Biol."},{"issue":"7","key":"10.1016\/j.bbr.2021.113201_bib0595","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1021\/acschemneuro.8b00126","article-title":"Discovery and optimization of potent and CNS penetrant M5-preferring positive allosteric modulators derived from a novel, chiral N-(indanyl)piperidine amide scaffold","volume":"9","author":"Bender","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"6","key":"10.1016\/j.bbr.2021.113201_bib0600","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bmcl.2017.02.020","article-title":"Continued optimization of the M5 NAM ML375: discovery of VU6008667, an M5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies","volume":"27","author":"McGowan","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bbr.2021.113201_bib0605","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41386-020-00915-1","article-title":"Sex differences in dopamine release regulation in the striatum","volume":"46","author":"Zachry","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2021.113201_bib0610","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/615356","article-title":"A role for estrogen in schizophrenia: clinical and preclinical findings","volume":"2015","author":"Gogos","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.bbr.2021.113201_bib0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112506","article-title":"A systematic review of sex-based differences in effectiveness and adverse effects of clozapine","volume":"280","author":"Alberich","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbr.2021.113201_bib0620","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12991-015-0075-x","article-title":"Sex differences in plasma clozapine and norclozapine concentrations in clinical practice and in relation to body mass index and plasma glucose concentrations: a retrospective survey","volume":"14","author":"Anderson","year":"2015","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.bbr.2021.113201_bib0625","unstructured":"Putative Cognitive Enhancer VU319. https:\/\/ClinicalTrials.gov\/show\/NCT03220295."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432821000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432821000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:27:42Z","timestamp":1759066062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432821000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":125,"alternative-id":["S0166432821000899"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2021.113201","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting muscarinic receptors to treat schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2021.113201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113201"}}